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A B S T R A C T
Background: The efﬁcacy and safety of transcatheter aortic valve implantation (TAVI) in Asian
populations were unknown. The purpose of this study was to compare directly the clinical outcomes
of the ﬁrst Japanese trial and a European single-center experience after TAVI.
Methods and results: Between April 2010 and October 2011, 64 patients were included in the PREVAIL
JAPAN multicenter trial which was set up to evaluate the safety and efﬁcacy of the Edwards SAPIEN XTTM
(Edwards Lifesciences, Irvine, CA, USA) in high-risk Japanese patients with severe aortic stenosis.
Between March 2010 and January 2012, 237 consecutive patients treated with TAVI using the Edwards
SAPIEN XTTM prosthesis at Institut Cardiovasculaire Paris Sud were prospectively included in the Massy
cohort. We compared the clinical outcomes of these two cohorts. Patients were of similar age (83.4  6.6
years vs. 84.5  6.1 years, p = 0.25), but logistic EuroSCORE was higher in the Massy cohort (20.2  11.7% vs.
15.6  8.0%, p < 0.01). Body surface area was smaller in the PREVAIL JAPAN cohort (1.41  0.14 m2 vs.
1.72  0.18 m2; p < 0.01) as was the annulus diameter (20.4  1.46 mm vs. 22.0  1.84 mm, p < 0.01). The
transfemoral approach was used in 57.8% in the Japanese cohort vs. 51.5% in the Massy cohort. Device success
was similar (89.1% vs. 94.1%, p = 0.21, respectively), as well as 30-day and 6-month survival rates (92.2% vs.
90.7% and 89.1% vs. 83.1%, p = 0.71 and p = 0.25, respectively). The incidence of major vascular complications
was not signiﬁcantly different between the two groups (9.4% vs. 5.9%, p = 0.23, respectively). A higher post-
procedural mean pressure gradient was observed in the PREVAIL JAPAN cohort (12.7  11.4 mmHg vs.
10.1  3.6 mmHg, p = 0.01), but satisfactory improvement in 6-month functional status was obtained in both
cohorts (76.5% vs. 77.2%, p = 0.91).
Conclusions: Clinical outcomes after TAVI in the patients included in the PREVAIL JAPAN trial were
acceptable and as safe as that of a single-center European cohort.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Transcatheter aortic valve implantation (TAVI) is evolving
rapidly with an exponential growth of procedures in European
countries [1,2]. Although this technique has reached relative
maturity in Europe, its efﬁcacy and safety in Asian patients have
not been thoroughly investigated. Furthermore, Asian populations
have smaller body size and, consequently, smaller aortic annulus
size and smaller vascular access compared with their European
counterparts. The risks related to these anatomical characteristics
have raised serious concerns about the safety of TAVI procedures in
Asian patients.
Transfemoral (TF) and transapical (TA) Placement of Aortic
Balloon Expandable Transcatheter Valves Trial (PREVAIL JAPAN) is
a single-arm, prospective, multicenter, non-randomized, pivotal
clinical trial evaluating the safety and efﬁcacy of the Edwards
SAPIEN XTTM transcatheter heart valve (Edwards Lifesciences,
Irvine, CA, USA) in Japanese patients with severe aortic stenosis
(AS) [3].
The purpose of this study was to compare the clinical
outcomes of patients undergoing TAVI with the SAPIEN XTTM
valve between the PREVAIL JAPAN trial and a European single-
center patient cohort in order to determine the future of TAVI in
Asian countries.
Methods
Study population and design
PREVAIL JAPAN
PREVAIL JAPAN is a single-arm, prospective, multicenter, non-
randomized, pivotal clinical trial evaluating the Edwards SAPIEN
XTTM transcatheter heart valve, NovaFlexTM TF delivery system, the
Ascendra2TM TA delivery system and crimper accessories (Edwards
Lifesciences). The purpose of this trial was to evaluate the safety
and efﬁcacy of the SAPIEN XTTM prosthesis for Japanese patients
with severe symptomatic AS attributed to calciﬁcation and
degeneration of a valve leaﬂet and in whom surgical treatment
would carry signiﬁcant risks.
Between April 2010 and October 2011, 64 patients (TF
approach: 37 patients; TA approach: 27 patients) were included
in the trial [3]. Inclusion criteria were the presence of symptomatic
degenerative AS with New York Heart Association (NYHA) Class II
or greater, a mean gradient >40 mmHg or jet velocity greater than
4.0 m/s, or aortic valve area <0.8 cm2 (or effective oriﬁce area
index <0.5 cm2/m2). Patients for whom TAVI was deemed to be the
best treatment option were selected based on the clinical
consensus of a multidisciplinary team consisting of cardiac
surgeons, interventional cardiologists, anesthetists, and imaging
specialists. Primary exclusion criteria were the following: bicuspid
or non-calciﬁed aortic valve, aortic annulus diameter (echo
measurement) <18 mm or >25 mm, aortic dissection or iliac-
femoral dimensions or disease precluding safe sheath insertion
(especially calciﬁcation), severe left ventricular dysfunction (left
ventricular ejection fraction <20%), untreated coronary artery
disease requiring revascularization, severe aortic regurgitation or
mitral regurgitation (>3+) or prosthetic valve (any location),
serum creatinine >3.0 mg/dL or dialysis dependent, acute myo-
cardial infarction in the previous month, upper gastrointestinal
bleeding in the previous 3 months, cerebrovascular accident or
transient ischemic attack in the previous 6 months, any cardiac
procedure other than balloon aortic valvuloplasty during the
previous month or in the previous 6 months for drug-eluting stents,
and hemodynamic instability (i.e. requiring inotropic support).
The clinical sites participating in this trial were Osaka
University Hospital (Osaka, Japan), Kurashiki Central Hospital(Okayama, Japan), and Sakakibara Heart Institute (Tokyo,
Japan).
All new sites underwent a structured program of training and
proctorship. Teams from the new institution visited a training
center for didactic and simulator training. Proctors attended or
commented on every case involving each approach at each new
institution.
The Massy series
Between March 2010 and January 2012, a total of 237
consecutive high-risk patients with symptomatic severe AS treated
with TAVI using the Edwards SAPIEN XTTM prosthesis at the
Institut Cardiovasculaire Paris Sud (Massy, France) were prospec-
tively included in the study group designated as the Massy cohort.
Patients with severe symptomatic AS (valve area 1.0 cm2) were
considered candidates for TAVI if they had a logistic EuroSCORE
>20%, or if surgery was deemed to be of excessive risk due to
signiﬁcant comorbidities, or if other risk factors not captured by
these scoring systems (e.g. porcelain aorta) were present. The
decision to proceed with TAVI was discussed by a dedicated heart
team including experienced clinical and interventional cardiolo-
gists, cardiovascular surgeons, and anesthesiologists. All patients
agreed to participate in the study, and written informed consent
was obtained in all cases.
Patients were selected to undergo TAVI via the TF approach or
alternative approaches depending on the size, calciﬁcation, and
tortuosity of the ilio-femoral arterial access. The transaortic
approach (TA) was used as an alternative in cases of unsuitable
femoral arterial access. The valve prosthesis size was selected
according to the diameter of the aortic annulus, which in the early
stages of the Massy series was systematically measured using
transesophageal echocardiography, and more recently by comput-
ed tomography (CT) scan using the calculated average annulus
diameter [4]. Both measurements were performed in compliance
with currently available recommendations [5–7]. All procedures
and valve sizing were performed by an experienced team
according to standard operating procedures, as previously
described [8].
Endpoint deﬁnitions for both studies
The main endpoints of this study were all-cause mortality at
6-month follow-up, major vascular complications, 30-day safety
composite endpoint, and device success as deﬁned by the Valve
Academic Research Consortium (VARC) criteria [9]. Vascular
complications were deﬁned by the VARC criteria [9], as well as
the combined 30-day safety endpoint (all-cause mortality, major
stroke, life-threatening or disabling bleeding, acute kidney injury
stage 3, peri-procedural myocardial infarction, major vascular
complication, and further intervention due to valve dysfunction).
Device success was deﬁned as the achievement of successful
vascular access, delivery and deployment of the device and
successful retrieval of the delivery system, correct positioning of
the device, intended performance of the prosthetic heart valve
with aortic valve area >1.2 cm2 and mean aortic valve gradient
<20 mmHg or peak velocity <3 m/s, without moderate or severe
prosthetic valve regurgitation and with only one valve implanted
in the proper anatomical location.
Statistical analysis
Quantitative variables are expressed as mean  standard
deviation and qualitative variables as numbers and percentages.
Comparison of quantitative variables was performed with an
unpaired Student t-test or Wilcoxon rank sum test, depending on
Table 2
Procedural characteristics.
PREVAIL JAPAN Massy p
Patient number, n 64 237
Transfemoral 37 (57.8%) 122 (51.5%) <0.01
Transapical 27 (42.2%) 40 (16.9%)
Transaortic 0 (0%) 75 (31.6%)
Valve size, mm
Edwards 23 mm 46 (71.9%) 62 (26.2%) <0.01
Edwards 26 mm 18 (28.1%) 142 (59.9%)
Edwards 29 mm 0 (0%) 33 (13.9%)
Post-dilatation 5 (7.8%) 22 (9.3%) 0.71
Contrast volume, ml 167.5  68.3 140.1  56.3 <0.01
Fluoro time, min 24.1  11.8 17.8  12.5 <0.01
Procedure time, min 118.4  61.6 81.8  34.9 <0.01
Values are expressed as n (%) or mean  SD.
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used to compare qualitative variables. Statistical signiﬁcance was
deﬁned as p < 0.05. The data were analyzed using PASW statistics
19.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The baseline characteristics of the two study groups are shown
in Table 1. Although mean age, gender distribution, the rate of
diabetes, hyperlipidemia, coronary artery disease, previous coro-
nary artery bypass grafting, peripheral artery disease, cerebrovas-
cular disease, and chronic pulmonary obstructive disease were
similar for both study groups, statistically signiﬁcant differences
were observed with respect to height, weight, body surface area,
body mass index, the rate of hypertension, NYHA class III or IV,
previous myocardial infarction, estimated glomerular ﬁltration
rate, logistic EuroSCORE, STS score, aortic valve area, mean
pressure gradient, left ventricular ejection fraction, aortic annulus
measured by echo and CT, and aortic regurgitation. The resulting
logistic Euroscore of 15.6% for the PREVAIL JAPAN group and 20.2%
for the Massy study group (p < 0.01) showed that the Massy cohort
was composed of a higher-risk patient population.
Procedural characteristics
The TF approach was implemented in 50% of patients in both
the PREVAIL JAPAN and the Massy study group. In the MassyTable 1
Study population.
PREVAIL JAPAN Massy p
Patient number, n 64 237
Age, years 84.5  6.1 83.4  6.6 0.25
Male gender 22 (34.4%) 100 (42.2%) 0.26
Height, cm 149.6  8.3 161.6  8.7 <0.01
Weight, kg 48.8  8.8 68.0  13.4 <0.01
BSA, m2 1.41  0.14 1.72  0.18 <0.01
BMI, kg/m2 21.8  3.8 26.0  4.5 <0.01
Diabetes 11 (17.2%) 55 (23.2%) 0.30
Hyperlipidemia 32 (50.0%) 117 (49.4%) 0.93
Hypertension 57 (89.1%) 162 (68.4%) <0.01
NYHA class III/IV 28 (43.8%) 206 (86.9%) <0.01
Coronary artery disease 31 (48.4%) 134 (56.5%) 0.25
Previous MI 22 (34.4%) 25 (10.5%) <0.01
Previous CABG 6 (9.4%) 30 (12.7%) 0.47
Previous PCI 21 (32.8%) 50 (21.1%) 0.05
Peripheral artery disease 15 (23.4%) 66 (27.8%) 0.48
Cerebrovascular disease 2 (3.1%) 18 (7.6%) 0.16
COPD 17 (26.6%) 59 (24.9%) 0.79
eGFR 46.0  22.5 57.2  24.2 <0.01
eGFR <60 ml/min 50 (78.1%) 144 (60.8%) <0.01
Logistic EuroSCORE, % 15.6  8.0 20.2  11.7 <0.01
STS score, % 9.0  4.5 7.1  4.3 <0.01
Aortic valve area, cm2 0.55  0.13 0.65  0.14 <0.01
Aortic valve area index, cm2/m2 0.39  0.10 0.36  0.11 0.08
Mean pressure gradient, mmHg 59.6  22.3 48.6  17.8 <0.01
LVEF, % 59.5  9.9 54.5  14.2 <0.01
LVEF <40% 4 (6.3%) 54 (22.9%) <0.01
Diam-TEE, mm 20.4  1.46 22.0  1.84 <0.01
Aortic regurgitation (0–4) 1.44  0.79 0.96  0.74 <0.01
Diam-CT, mm – 23.2  1.77
Values are expressed as n (%) or mean  SD.
BSA, body surface area; BMI, body mass index; NYHA, New York Heart Association;
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary
artery bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; Diam-TEE, aortic
annulus diameter measured by transesophageal echography; Diam-CT, aortic
annulus diameter measured by computed tomography.cohort, 31.6% of patients underwent TAVI via the transaortic
approach. The most commonly used implant was the Edwards
23 mm valve (71.9%) in the PREVAIL JAPAN group and the Edwards
26 mm valve (59.9%) in the Massy cohort. Smaller valve size
was selected in the PREVAIL JAPAN cohort compared with
the Massy group (23.9  1.37 mm vs. 24.8  1.48 mm, p < 0.01).
The Edwards 29 mm valve was used in 13.9% of the Massy cohort.
The amount of contrast volume, as well as ﬂuoro time and
procedure time were signiﬁcantly higher in the PREVAIL JAPAN
group compared with the Massy group (Table 2).
Procedural characteristics of the study population, transfemoral
approach
Procedural characteristics of the patients using the TF approach
are shown in Table 3. A total of 37 patients (57.8%) in the PREVAIL
JAPAN cohort and 122 patients (51.5%) in the Massy group
underwent TF TAVI. Sheath size and femoral artery diameter were
not signiﬁcantly different between the two cohorts. All patients
underwent TAVI under general anesthesia in the PREVAIL JAPAN
cohort, whereas almost all patients had local anesthesia and
neuroleptanalgesia in the Massy cohort. The rate of percutaneous
closure was signiﬁcantly higher in the Massy group compared with
the PREVAIL JAPAN patients.
Post-procedural outcomes
Post-procedural outcomes are shown in Table 4. The incidence
of major vascular complications was not signiﬁcantly different
between the two study cohorts: 9.4% in the PREVAIL JAPAN group
and 5.9% in Massy (p = 0.23). The incidence of cardiac tamponade,
annulus rupture, valve migration, conversion to open heart
surgery, cerebrovascular accidents, transfusion, transfusion over
4 units, acute kidney injury stage 3, device success, newTable 3
Procedural characteristics of the study population, transfemoral.
PREVAIL JAPAN Massy p
Patient number, n 37 122
Sheath size, Fr 18.4  0.5 18.3  1.1 0.57
14 Fr 0 (0%) 2 (1.6%) 0.16
16 Fr 0 (0%) 9 (7.3%)
18 Fr 23 (62.2%) 52 (42.6%)
19 Fr 14 (37.8%) 58 (47.5%)
22 Fr 0 (0%) 1 (0.8%)
General anesthesia 37 (100%) 1 (0.8%) <0.01
Femoral artery diameter, cm 7.59  0.83 7.53  1.21 0.46
Percutaneous closure 9 (24.3%) 120 (98.4%) <0.01
Values are expressed as n (%) or mean  SD.
Table 4
Post-procedural outcomes of the study population.
PREVAIL JAPAN Massy p
Patient number 64 237
Major vascular complication 6 (9.4%) 14 (5.9%) 0.23
Cardiac tamponade 3 (4.7%) 8 (3.6%) 0.47
Annulus rupture 1 (1.6%) 4 (1.2%) 0.84
Valve migration 2 (3.1%) 2 (0.8%) 0.20
Conversion to open heart surgery 3 (4.7%) 6 (2.5%) 0.29
Cerebrovascular accidents 2 (3.1%) 5 (2.6%) 0.55
Transfusion 24 (37.5%) 79 (35.1%) 0.73
Transfusion over 4 unit 13 (20.3%) 30 (12.7%) 0.12
Acute kidney injury stage 3 2 (3.1%) 1 (0.4%) 0.12
Device success 57 (89.1%) 222 (94.1%) 0.21
Post-implantation
Mean pressure gradient, mmHg 12.7  11.4 10.1  3.6 0.01
LVEF, % 59.0  9.14 55.6  12.3 0.12
Aortic regurgitation 2 12 (18.8%) 77 (24.0%) 0.36
New pacemaker 5 (7.8%) 14 (6.0%) 0.58
Combined safety endpoint (30 days) 16 (25.0%) 34 (14.3%) 0.04
30-day survival 59 (92.2%) 214 (90.7%) 0.71
6-month survival 57 (89.1%) 197 (83.1%) 0.25
6-month NYHA improvement 49 (76.5%) 183 (77.2%) 0.91
Values are expressed as n (%) or mean  SD.
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
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improvement were similar for both cohorts. Post-procedural aortic
regurgitation and left ventricular ejection fraction were also
similar in both cohorts. The incidence of 30-day combined safety
endpoints was signiﬁcantly higher in the PREVAIL JAPAN cohort
(25.0% vs. 14.3%, p = 0.04). The post-procedural mean pressure
gradient was signiﬁcantly higher in the PREVAIL JAPAN cohort
(12.7  11.4 vs. 10.1  3.6, p = 0.01).
Discussion
This study is the ﬁrst of its kind to compare the clinical
outcomes between a European and an Asian cohort of patients
undergoing TAVI. The results suggest that TAVI can be carried out
safely in Japanese patients with acceptable 30-day and 6-month
results compared with a European single-center experience.
TAVI has emerged as a viable therapeutic option for patients
with severe symptomatic AS who are ineligible or high-risk for
conventional surgical aortic valve replacement [1,8,10]. Although
this technique has reached relative maturity in European
countries, its efﬁcacy and safety in Asian patients have not been
investigated. Furthermore, Asian populations are of smaller body
size and, therefore have a smaller aortic annulus size and smaller
vascular access compared with European populations. Smaller
aortic annulus size may be associated with a higher risk of annulus
rupture as well as an increased frequency of patient-prosthesis
mismatch resulting in a residual post-procedural pressure gradi-
ent. Smaller vascular access may lead to relative oversizing of the
current prevalent devices and a higher risk of potential concomi-
tant vascular complications [8,11]. These characteristics are a
source of serious concern for the Asian patients who undergo TAVI.
In this study, a higher incidence of vascular complications was
observed in the PREVAIL JAPAN cohort, possibly because patients
in the PREVAIL JAPAN cohort had signiﬁcantly smaller body size
and smaller vascular access compared with the European study
group. However, the results were still acceptable given the fact that
the operators in the PREVAIL JAPAN trial were at an earlier stage of
their experience compared with their European counterparts. In
the PREVAIL JAPAN cohort, the majority of patients underwent
surgical vascular closure, and only 24.3% patients in the TF cohort
had percutaneous closure. Surgical closure may be a better option
than percutaneous closure in terms of bleeding especially foroperators who are less experienced in percutaneous devices. One
report from the PREVAIL JAPAN trial demonstrated the effective-
ness of direct iliac surgical access in patients with difﬁcult femoral
access [12]. In the Massy cohort, the incidence of vascular
complications decreased inversely in relation to increasing
operator experience in the use of percutaneous devices [13].
Although care should be taken to avoid vascular complications in
smaller body size patients with smaller vascular access, increasing
operator experience coupled with enhanced technology allowing a
reduction in sheath size should enable the operators to gradually
switch to percutaneous closure methods in Japanese patients
undergoing TAVI [14,15]. Surgical aortic valve replacement for
severe AS in patients of small body size remains challenging,
especially in those with a small aortic annulus, due to the
frequency of patient-prosthesis mismatch (PPM) resulting in a
higher residual post-procedural pressure gradient [16–18]. PPM is
associated with lower improvement rates in symptoms, functional
class, and left ventricular function, and also has a potential impact
on long-term mortality [17,19–21]. Few studies have been
reported regarding PPM following TAVI. In a recent report, PPM
was associated with a lower rate of functional improvement after
implantation of a balloon expandable valve, although no signiﬁ-
cant difference was observed in the occurrence of major adverse
cardiovascular events [22]. Another study showed that TAVI for
small annulus size using a 23-mm Edwards SAPIEN bioprosthesis
was associated with a low incidence of severe PPM [23]. In this
study, post-procedural mean pressure gradient was higher in the
PREVAIL JAPAN cohort compared to the Massy study group
(12.7  11.4 mmHg vs. 10.1  3.6 mmHg, p = 0.01). However, satis-
factory post-procedural hemodynamic results were observed and the
rate of NYHA improvement after TAVI was not signiﬁcantly different
between the two cohorts. Annulus rupture is another important issue
for patients with a small aortic annulus undergoing TAVI. A recent
report has shown that annulus rupture with balloon-expandable TAVI
is associated with prosthesis oversizing [24]. Patients with a small
aortic annulus run a potential risk of prosthesis oversizing. In the
current study, the incidence of annulus rupture was low even in
the PREVAIL JAPAN cohort with smaller aortic annulus diameters.
Precise annulus assessment and sizing may reduce the incidence of
annulus rupture. Recent studies suggest that CT-based annulus sizing
is the best available method to select the appropriate prosthesis size
for TAVI [4,25]. The introduction of smaller valves such as a 20-mm
balloon expandable transcatheter heart valve should also contribute
to reducing the risk of annulus rupture in Asian patients with smaller
annulus [26].
In the TF cohort, the majority of patients in the Massy group had
TAVI under local anesthesia with neuroleptanalgesia, while all
patients received general anesthesia in the PREVAIL JAPAN cohort.
A recent study has shown that TAVI under conscious sedation is as
safe and effective as TAVI under general anesthesia and is
associated with reduced total procedure time [27]. In our study,
a reduction in procedure time, ﬂuoro time, and contrast volume
was observed in the Massy group compared to that in the PREVAIL
JAPAN cohort. With increasing experience, anesthesia methods
should become less invasive with lower volumes of contrast media
being used in Asian patients undergoing TAVI.
The rapidly increasing clinical experience in many European
centers has resulted in a gradual improvement in clinical outcomes
after TAVI [13,28]. The prevalence of TAVI in Asian countries is also
expected to increase in the near future.
Study limitation
This non-randomized observational study compared the results
between a clinical trial in Japan and a single-center experience in
Europe. Furthermore, because of single-center experience, the
Y. Watanabe et al. / Journal of Cardiology 65 (2015) 112–116116results from the European cohort do not mean the results of all of
Europe. Patient treatment bias is inherent in non-randomized
observational studies, and may have affected the comparison of
clinical outcomes between the PREVAIL JAPAN cohort and the
Massy study group. The PREVAIL JAPAN cohort is under clinical
trial so the situation in relation to the patient’s selection is totally
different from that of the European cohort which is under daily
patient selection. The learning curve may have also played an
important role and had an impact on the results in the PREVAIL
JAPAN study. Further studies of larger patient populations are
required to conﬁrm our results.
Conclusions
This study provides the ﬁrst comparison of clinical outcomes
between a European and an Asian cohort of patients undergoing
TAVI. The clinical outcome after TAVI in the PREVAIL JAPAN cohort
was as safe and satisfactory as that of the European single-center
experience. The results of this study should encourage widespread
use of TAVI in Asian patients.
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